

- Kajihara I, Makino T, Fukushima S, Inoue Y, Okamoto Y, Hasegawa M, Fujimoto M, Ihn H: miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin $\beta 3$. *Am J Pathol*. 182(1): 206–16, 2013.
2. Makino K, Jinnin M, Aoi J, Hirano A, Kajihara I, Makino T, Sakai K, Fukushima S, Inoue Y, Ihn H: Diccoidin domain receptor 2—micro RNA 196 a—mediated negative feedback against excess type I collagen expression is impaired in scleroderma dermal fibroblasts. *J Invest Dermatol*. 133(1): 110–9, 2013.
3. Kajihara I, Jinnin M, Yamane K, Makino T, Honda N, Igata T, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, Ihn H: Increased accumulation of thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts. *Am J Pathol*. 180(2): 703–14, 2012
4. Honda N, Jinnin M, Kajihara I, Makino T, Makino K, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, Ihn H: TGF- β -mediated down-regulation of microRNA-196 a contributes to the constitutive up-regulated type I collagen expression in scleroderma dermal fibroblasts. *J Immunol*. 188(7): 3323–31, 2012.
5. Nakashima T, Jinnin M, Yamane K, Honda N, Kajihara I, Makino T, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, Ihn H: Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. *J Immunol*. 188(8): 3573–83, 2012
6. Asano Y, Ihn H, Jinnin M, Tamaki K, Sato S: Altered dynamics of TGF- β receptors in scleroderma fibroblasts. *Ann Rheum Dis*. 70(2): 384–7, 2011.
7. Moriya C, Jinnin M, Yamane K, Maruo K, Muchemwa FC, Igata T, Makino T, Fukushima S, Ihn H: Expression of matrix metalloproteinase-13 is controlled by IL-13 via PI3K/Akt3 and PKC- δ in normal dermal fibroblasts. *J Invest Dermatol*. 131(3): 655–61, 2011
- <岡晃>
1. Improved loop-mediated isothermal amplification for HLA-DRB1 genotyping using RecA and a restriction enzyme for enhanced amplification specificity. Mitsunaga S, Shimizu S, Okudaira Y, Oka A, Tanaka M, Kimura M, Kulski JK, Inoue I, Inoko H. *Immunogenetics*. 2013 Jun; 65(6): 405–15.
2. IL12B and IL23R gene SNPs in Japanese psoriasis. Oka A, Mabuchi T, Ikeda S, Terui T, Haida Y, Ozawa A, Yatsu K, Kulski JK, Inoko H. *Immunogenetics*. 2013 Nov; 65(11): 823–8.
3. Super high resolution for single molecule-sequence-based typing of classical HLA loci at the 8-digit level using next generation sequencers. Shiina T, Suzuki S, Ozaki Y, Taira H, Kikkawa E, Shigenari A, Oka A, Umemura T, Joshita S, Takahashi O, Hayashi Y, Paumen M, Katsuyama Y, Mitsunaga S, Ota M, Kulski JK, Inoko H. *Tissue Antigens*. 2012 Oct; 80(4): 305–16.
- <川口鎮司>
1. Ota Y, Kawaguchi Y, Takagi K, Ichida H, Gono T, Hanaoka M, Higuchi T, Yamanaka H. Ghrelin attenuates collagen production in lesional fibroblasts from patients with systemic sclerosis. *Clin Immunol* 147: 71–78, 2013
2. Terao C, Ohmura K, Kawaguchi Y, Nishimoto T,

Kawasaki A, Takehara K, Furukawa H, Kochi Y, Ota Y, Ikari K, Sato S, Tohma S, Yamada R, Yamamoto K, Kubo M, Yamanaka H, Kuwana M, Tsuchiya N, Matsuda F, Mimori T. PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population. *Arthritis Rheum* 65: 472–480, 2013

3. Odani T, Yasuda S, Ota Y, Fujieda Y, Kon Y, Horita T, Kawaguchi Y, Atsumi T, Yamanaka H, Koike T. Up-regulated expression of HLA-DRB5 transcripts and high frequency of the HLA-DRB5*01: 05 allele in scleroderma patients with interstitial lung disease. *Rheumatology* 51: 1765–1774, 2012
4. Takagi K, Kawaguchi Y, Kawamoto M, Ota Y, Tochimoto A, Gono T, Katsumata Y, Takagi M, Hara M, Yamanaka H: Activation of the activin A-Alk-Smad pathway in systemic sclerosis. *J Autoimmunity* 36: 181–188, 2011
5. Tochimoto A, Kawaguchi Y, Hara M, Tateishi M, Fukasawa C, Takagi K, Nishimagi E, Ota Y, Katsumata Y, Gono T, Tanaka E, Yamanaka H: Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: four-year follow-up. *Modern Rheumatol* 21: 296–301, 2011

<桑名正隆>

1. Kaji K, Noreen F, Medsger TA Jr, Satoh T, Hoshino K, Hamaguchi Y, Hasegawa M, Lucus M, Schnure A, Ogawa F, Sato S, Takehara K, Fujimoto M, and Kuwana M. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. *Arthritis Care Res*. In press.
2. Kuwana M, and Okazaki Y. Impaired in vivo neovas-

cularization capacity of endothelial progenitor cells in patients with systemic sclerosis. *Arthritis Rheum*. In press.

3. Kuwana M, Okazaki Y. Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols. *Ann Rheum Dis* In press.
4. Masuda A, Yasuoka H, Satoh T, Okazaki Y, Yamaguchi Y, and Kuwana M. Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop. *Arthritis Res. Ther.* 2013; 15(4): R74.
5. Kuwana M, Watanabe H, Matsuoka N, and Sugiyama N. Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials. *BMJ Open*. 2013; 3: e003113.
6. Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, and Kuwana M. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-center cohort. *Rheumatology*. 2012; 51(10): 1846–1854.
7. Furuya Y, Kuwana M. Effect of bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. *J. Rheumatol*. 2011; 38(10): 2186–2192.
8. Hoshino K, Satoh T, Kawaguchi Y, Kuwana M. Association of Hepatocyte Growth Factor promoter polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis. *Arthritis Rheum*. 2011; 63(8): 2465–2472.

<後藤大輔>

1. Segawa S, Goto D, Yoshiga Y, Horikoshi M, Sugihara M, Hayashi T, Chino Y, Matsumoto I, Ito S,

Sumida T. Involvement of NK1.1 + $\gamma\delta$ T Cells in the IL-18 Plus IL-2-Induced Interstitial Lung Disease. *Am J Respir Cell Mol Biol.* 2011; 45(3): 659–66.

<高橋裕樹>

1. Shimizu Y, Yamamoto M, Naishiro Y, Sudoh G, Ishigami K, Yajima H, Tabeya T, Matsui M, Suzuki C, Takahashi H, Seki N, Himi T, Yamashita K, Noguchi H, Hasegawa T, Suzuki Y, Honda S, Abe T, Imai K, Shinomura Y. Necessity of early intervention for IgG4-related disease-delayed treatment induces fibrosis progression. *Rheumatology* 2013; 52; 679–683.
2. Yamamoto M, Tabeya T, Naishiro Y, Yajima H, Ishigami K, Shimizu Y, Obara M, Suzuki C, Yamashita K, Yamamoto H, Hayashi T, Sasaki S, Sugaya T, Ishida T, Takano KI, Himi T, Suzuki Y, Nishimoto N, Honda S, Takahashi H, Imai K, Shinomura Y. Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic disease and other diseases. *Mod Rheumatol* 2012; 22; 419–425.

<藤本学>

1. Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Tedder TF, Fujimoto M. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. *Blood*, 2013; 121: 3274–83.
2. Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M. FTY720 ameliorates murine Scl-cGVHD by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. *Arthritis Rheum.* 2013; 65: 1624–35.

3. Ueda-Hayakawa I, Hasegawa M, Hamaguchi Y, Takehara K, Fujimoto M. Circulating δ/γ T cells in systemic sclerosis exhibit activated phenotype and enhance gene expression of pro α 2 (I) collagen of fibroblasts. *J Dermatol Sci.* 2013; 69: 54–60.

4. Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Huu DL, Iwakura Y, Fujimoto M, Takehara K. Potential roles of interleukin 17A in the development of skin fibrosis. *Arthritis Rheum.* 2012; 64: 3726–35.
5. Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. *J Invest Dermatol.* 2012; 132: 2752–61.

<山本俊幸>

1. Yamamoto T. Updates in the pathophysiology in dermal sclerosis. *Expert Rev Dermatol* 2012, 7; 559–568.

2. 学会発表

(1) 国内

<佐藤 伸一>

1. 佐藤伸一：教育講演 7. 膠原病の自己抗体の読み方・考え方 第76回日本皮膚科学東京支部学術大会京王プラザホテル（東京）2013/02/16～2013/03/17
2. 佐藤伸一：強皮症。日本皮膚科学会教育講習会（東京）2013.
3. 佐藤伸一：強皮症の臨床。リウマチ財団愛媛地区教育研修会（愛媛）2012

<浅野善英>

1. 増井友里、浅野善英、柴田彩、野田真史、青笹尚彦、赤股要、山田大資、玉城善史郎、多田弥生、菅谷誠、門野岳史、佐藤伸一 全身性強皮症の病態におけるアディポネクチンの役割 第

39 回日本臨床免疫学会総会 東京 2011 年 9 月 16 日

2. 浅野善英、玉城善史郎、久保正英、尹浩信、佐藤伸一 Rapamycin が強皮症皮膚線維芽細胞に対して抗線維化作用を示すメカニズム 第 39 回日本臨床免疫学会総会 東京 2011 年 9 月 16 日

<石川治>

1. 石渕隆広 周東朋子 田中撰子 田子 修 永井弥生 石川 治 クレアチンキナーゼ上昇を伴った限局性強皮症の 1 例第 76 回日本皮膚科学会東京支部学術大会 2013.2.16 - 17
2. 服部友保 永井弥生 石川 治 全身性強皮症に伴った胃逆流性食道炎に対するエソメプラゾールの効果第 76 回日本皮膚科学会東部支部学術大会 2012.9.29-30 札幌
3. 竹内裕子 服部友保 清水 晶 永井弥生 石川 治 全身性強皮症における皮膚線維化とリンパ管数との関連 第 111 回日本皮膚科学会学術大会 2012.6.1 - 3 京都
4. 服部友保 永井弥生 田中撰子 石川 治 全身性強皮症の経過中に関節リウマチを併した症例の検討 第 35 回皮膚脈管膠原病研究会 2012.2.16-17 東京
5. Yoko Yokoyama, Masatoshi Abe, Osamu Ishikawa The effect of long-term silencing on proliferation and MMP-1 production of fibroblast from systemic Sclerosis patients The 36th Annual Meeting of the Japanese Society for Investigative Dermatology 2011.12.9-11, 2011

<尹浩信>

1. 尹浩信 : Expression analysis of multiple microRNA in each scleroderma patient.
2. 尹浩信 : Decreased adiponectin levels in the pa-

tients with diffuse cutaneous systemic sclerosis.

3. 尹浩信 : Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients.
4. 尹浩信 : Excessive expression of type I collagen in systemic and localized scleroderma is caused by the down-regulation of microRNA let-7 a.
5. 尹浩信 : microRNA-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin $\beta 3$.
6. 尹浩信 : Nakayama W, Jinnin M, Fukushima S, Ihn H. Interleukin-23 signaling contributes to the increased collagen production in scleroderma fibroblasts.
7. 尹浩信 : 全身性強皮症の臨床症状と最近の話題
8. 尹浩信 : 膠原病の皮膚潰瘍治療
9. 尹浩信 : microRNA-7 is down-regulated and mediates excess collagen expression in localized scleroderma.
10. 尹浩信 : Serum angiopoietin-like protein 3 concentrations in rheumatic diseases.
11. 尹浩信 : 血管内皮細胞特異的エンドセリン-1 ノックアウトマウスにおける創傷治癒ならびに皮膚硬化の検討
12. 尹浩信 : microRNA-7 is down-regulated and mediates excess collagen expression in localized scleroderma.
13. 尹浩信 : Significant decreased microRNA-196 a in the sera and skin of patients with localized scleroderma.
14. 尹浩信 : TGF- β -mediated down-regulation of DDR2 contributes to the excessive type I collagen expression in scleroderma dermal fibroblasts.

15. 尹浩信 : Down-regulation of microRN A-196 a contributes to the constitutive up-regulated type I collagen expression in scleroderma dermal fibroblasts.
 16. 尹浩信 : The expression profile of Toll-like receptor family in dermal fibroblasts of scleroderma patients.
 17. 尹浩信 : Scleroderma dermal fibroblasts overexpress vascular endothelial growth factor due to autocrine transforming growth factor β signaling.
 18. 尹浩信 : 強皮症関連病態における血清 microRNA-29 a
 19. 尹浩信 : 強皮症における Trombospondin-2 の役割
- <遠藤平仁>
1. 遠藤平仁 : 慢性腎疾患を有する強皮症に関する検討
- <川口鎮司>
1. 川口鎮司。膠原病に伴う肺高血圧症における多剤併用療法 2013 京都
 2. 川口鎮司。全身性強皮症の基礎と臨床 第 56 回日本リウマチ学会総会 2012 東京
 3. 川口鎮司。膠原病における肺動脈性肺高血圧症の病態と診断 第 55 回日本リウマチ学会総会 2011 神戸
- <桑名正隆>
1. 桑名正隆 : SSc の新規治療。第 57 回日本リウマチ学会総会 (京都)。2013. 4. (シンポジウム 16 : 膠原病の新規治療)
 2. 桑名正隆 : 教育研修講演 24 ; 全身性強皮症の早期診断と治療。第 57 回日本リウマチ学会総会 (京都)。2013. 4.
 3. 桑名正隆 : ランチョンセミナー6 ; 膠原病性肺高血圧症治療の実践。第 1 回日本肺高血圧学会学術集会 (東京)。2013. 10.
 4. 桑名正隆 : スイーツセミナー ; 強皮症の難治性病態とその対策。第 24 回日本リウマチ学会関東支部学術集会 (東京)。2013. 12.
5. 桑名正隆 : 強皮症の病態と新たな治療標的。第 49 回日本臨床分子医学会学術集会 (京都)。2012. 4. (シンポジウム 1 : 炎症の慢性化と臓器線維化)
 6. 桑名正隆 : 教育研修講演 1 ; 膠原病に合併する肺高血圧症の診断と治療。第 56 回日本リウマチ学会総会 (東京)。2012. 4
 7. 桑名正隆 : 強皮症における血管内皮前駆細胞異常とその是正を目指した新たな治療戦略。第 40 回日本臨床免疫学会 (東京)。2012. 9. (ワークショップ 2 : 免疫疾患における再生医学)
 8. 桑名正隆 : カレントシンポジウム ; 膠原病の診療最前線 ; 強皮症。第 55 回日本リウマチ学会総会 (神戸)。2011. 7.
- <後藤大輔>
1. Segawa S, Goto D, Horikoshi M, Matsumoto I, Sumida T. Involvement of TCR V delta1 + NKT cells in systemic sclerosis patients with interstitial pneumonia. Annual Meeting of The Japanese Society for Immunology, 2013, Chiba, Dec.11-13, 2013
 2. 瀬川誠司、後藤大輔、堀越正信、近藤裕也、松本 功、住田孝之。間質性肺炎合併強皮症における TCR V δ 1 + NKT 細胞の解析。第 57 回日本リウマチ学会総会・学術集会、京都、2013 年 4 月 18-20 日
 3. Segawa S, Goto D, Horikoshi M, Matsumoto I, Sumida T. The role of TCR V delta1 + NKT cells in systemic sclerosis patients with interstitial pneumonitis. 第 41 回日本免疫学術集会、神戸、2012 年 12 月 5-7 日
 4. 瀬川誠司、後藤大輔、堀越正信、松本 功、住田孝之。間質性肺炎合併膠原病患者における

CD161 + V δ 1 + $\gamma\delta$ T 細胞の解析。第 40 回日本臨床免疫学会、東京、2012 年 9 月 27–29 日

5. Segawa S, Goto D, Horikoshi M, Umeda N, Ogishima H, Kondo Y, Tsuboi H, Sugihara M, Matsumoto I, Sumida T. The role of V δ 1 + $\gamma\delta$ NKT cells in autoimmune disease patients with interstitial pneumonitis. The 4th East Asia Group of Rheumatology, Tokyo, October 15, 2011
6. 瀬川誠司、後藤大輔、堀越正信、松本 功、住田孝之。IL-2 + IL-18 誘導性間質性肺炎モデルにおける NK1.1 + $\gamma\delta$ T 細胞の解析。第 55 回日本リウマチ学会総会・学術集会、神戸、2011 年 7 月 17–20 日

<高橋裕樹>

1. 鈴木知佐子、矢島秀教、清水悠以、田邊谷徹也、山本元久、苗代康可、高橋裕樹、篠村恭久。抗セントロメア抗体陽性シェーグレン症候群の自然経過に関する検討。2013：第 22 回日本シェーグレン症候群学会、大阪。
2. 鈴木知佐子、清水悠以、石上敬介、田邊谷徹也、矢島秀教、山本元久、苗代康可、高橋裕樹、篠村恭久、肥田時征。自己免疫性肝炎が先行し、著明な関節破壊と皮下石灰化を呈した全身性強皮症の一例。2013：第 23 回日本リウマチ学会北海道・東北支部学術集会。仙台。

<波多野将>

1. 波多野将：Pulmonary Arterial Hypertension Associated with Connective Tissue Disease, 第 17 回日本心不全学会学術集会シンポジウム 10。肺高血圧診療の新しいガイドライン。2013 年 11 月 29 日
2. 波多野将：The challenge to refractory pulmonary hypertension associated with scleroderma. The 13th International Conference on Endothelin. 2013 年 9

月 10 日

<藤本学>

1. 藤本 学 膠原病 update 第 77 回日本皮膚科学会東部支部学術大会（シンポジウム）2013 年 9 月 22 日 大宮
2. 藤本 学 強皮症 第 111 回日本皮膚科学会総会（教育講演）2012 年 6 月京都
3. 藤本 学 強皮症 第 62 回日本皮膚科学会中部支部学術大会（シンポジウム）2011 年 11 月 四日市

(2) 海外

<佐藤伸一>

1. Special Lecture. Scleroderma: present and Future. 64th KDA Spring meeting, Deagu, Korea, 2012

<浅野善英>

1. Akamata K, Asano Y, Noda S, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Trojanowska M, Sato S. Bosentan improves vascular abnormalities in endothelial cell-specific Fli1 knockout mice by increasing the DNA binding ability of Fli1—a possible mechanism explaining the effect of bosentan on scleroderma vasculopathy. ACR/ARHP Annual Meeting 13, 27th Oct 2013, San Diego
2. Taniguchi T, Asano Y, Akamata K, Noda S, Takahashi T, Ichimura Y, Toyama T, Trojanowska M, Sato S. Fli1 haploinsufficiency exacerbates dermal fibrosis via activation of fibroblasts, endothelial cells and macrophages in bleomycin-treated mice. ACR/ARHP Annual Meeting 13, 29th Oct 2013, San Diego
3. Noda S, Asano Y, Nishimura S, Taniguchi T, Fujiu K, Manabe I, Akamata K, Takahashi T, Ichimura Y, Toyama T, Tsuruta D, Trojanowska M, Nagai R, Sato S. Downregulation of KLF5 and Fli1 cooperatively

contribute to distinct manifestations of systemic sclerosis in vitro and in vivo. ACR/ARHP Annual Meeting 13, 29th Oct 2013, San Diego

<石川治>

1. Sei-ichiro Motegi, Akihito Uehara, Kazuya Yamada, Akihiko Uchiyama, Sachiko Ogino, Yoko Yokoyama, Yuko Takeuchi, and Osamu Ishikawa. Norepinephrine-induced IL-6 regulates fibrosis in systemic sclerosis American College of Rheumatology Annual Meeting 2013, 10.26-30.2013, San Diego
2. Motegi S, Okada E, Uchiyama A, Yamada K, Uehara A, Ogino S, Takeuchi Y, Ishikawa O. Role of endothelin-1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis. International Investigative Dermatology 2013, May 8-11, Edinburgh
3. Uehara A, Yamada K, Uchiyama A, Ogino S, Ishikawa O, Motegi S. Norepinephrine-induced IL-6 regulates fibrosis in systemic sclerosis. International Investigative Dermatology 2013, May 8-11, Edinburgh

<尹浩信>

1. Hironobu Ihn: The effect of IL-17 on the extracellular matrix expression in dermal fibroblasts.
2. Hironobu Ihn: Dysregulated discoidin domain receptor 2-microRNA196 a –mediated negative feedback against excess type I collagen expression in scleroderma dermal fibroblasts.
3. Hironobu Ihn: microRNA-150 down-regulation contributes to the constitutive type I collagen over-expression in scleroderma dermal fibroblasts via the induction of integrin $\beta 3$.
4. Hironobu Ihn: The levels of adiponectin are de-

creased in the skin and sera of diffuse cutaneous systemic sclerosis patients.

5. Hironobu Ihn: Adverse effects of Bosentan in patients with systemic sclerosis-associated pulmonary arterial hypertension.
6. Hironobu Ihn: Down-regulation of microRNA-196 a contributes to the constitutive up-regulated type I collagen expression in scleroderma dermal fibroblasts.
7. Hironobu Ihn: Soluble leptin receptor in patients with systemic sclerosis.
8. Hironobu Ihn: Decreased adiponectin levels in the skin and sera of diffuse cutaneous systemic sclerosis patients.
9. Hironobu Ihn: Increased serum levels of SPARC in patients with localized scleroderma.
10. Hironobu Ihn: Mechanism of Fibrosis.

<遠藤平仁>

1. 遠藤平仁：強皮症におけるリポキシゲナーゼに関する研究
2. 遠藤平仁：強皮症の消化管病変診断における FGF19 測定の意義

<桑名正隆>

1. Yasuoka H, Stern K, Okazaki Y, Nishimoto T, Takeuchi T, Kuwana M: Up-regulated expression of CXCL5 in circulating platelets from patients with systemic sclerosis: a role in fibrosis. The 77th Annual Scientific Meeting of American College of Rheumatology (San Diego). 2013. 10.
2. Kaji K, Fertig N, Medsger TA Jr, Satoh T, Hoshino K, Hamaguchi Y, Hasegawa M, Lucas M, Schnure A, Ogawa F, Sato S, Takehara K, Fujimoto M, Kuwana M: Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with

diffuse cutaneous and skeletal muscle involvement. The 77th Annual Scientific Meeting of American College of Rheumatology (San Diego). 2013. 10.

3. Kuwana M, Shirai Y, Yasuoka H, Takeuchi T, Masui K: Utility of autoantibody testing for predicting risk of pulmonary arterial hypertension: a retrospective analysis in routine autoantibody laboratory. The 77th Annual Scientific Meeting of American College of Rheumatology (San Diego). 2013. 10.
4. Kuwana M: Angiogenesis and vasculogenesis in systemic sclerosis-review and gaps in the evidence. 2nd Systemic Sclerosis World Congress (Madrid). 2012. 2.
5. Kuwana M, Kaburaki J: Natural history of pulmonary function in patients with systemic sclerosis and interstitial lung disease. 2nd Systemic Sclerosis World Congress (Madrid). 2012. 2.
6. Kuwana M, Takeuchi T, Kaburaki J: Elevation of KL-6 at early disease course predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. The 76th Annual Scientific Meeting of American College of Rheumatology (Washington, DC). 2012. 11.
7. Kuwana M, Okazaki Y, Yasuoka H, Takeuchi T: Impaired in vivo neovascularization capacity of endothelial progenitor cells in patients with systemic sclerosis. The 75th Annual Scientific Meeting of American College of Rheumatology (Chicago). 2011. 11.

<後藤大輔>

1. Segawa S, Goto D, Horikoshi M, Matsumoto I, Sumida T. The regulatory role of TCR V δ 1 + NKT cells in systemic sclerosis patients with interstitial pneumonia 15th International Congress of

Immunology, Milan, Italy, Aug.22-27, 2013

2. Segawa S, Goto D, Horikoshi M, Kondo Y, Umeda N, Hagiwara S, Yokosawa M, Hirota T, Miki H, Tsuboi H, Ogishima H, Suzuki T, Matsumoto I, Sumida T. Involvement of TCR V delta1 + NKT cells in systemic sclerosis: association with interstitial pneumonia ACR 77th Annual Scientific Meeting, San Diego, CA, USA, Oct.26-30, 2013
3. Segawa S, Goto D, Horikoshi M, Hagiwara S, Umeda N, Ogishima H, Kondo Y, Tsuboi H, Sugihara M, Hayashi T, Chino Y, Matsumoto I, Sumida T. The role of CD161 + V δ 1 + $\gamma\delta$ T cells in systemic sclerosis patients with interstitial pneumonitis ACR 76th Annual Scientific Meeting, Washington, DC, USA, Nov.9-14, 2012

<藤本学>

1. Fujimoto M. Pathogenic and regulatory B cells in autoimmune disease. International investigative Dermatology 2013, May, 2013 Edinburgh, Scotland.
2. Hamaguchi Y, Tedder TF, Fujimoto M. B cells have a dual effect on pulmonary fibrosis induced by bleomycin in a mouse model. The 98th Annual Meeting of The American Association of Immunologists (Immunology 2011). May. 2011, San Francisco, US

<山本俊幸>

1. Updates on the pathophysiology of dermal sclerosis. Yamamoto T. 30th Annual Conference of the Egyptian Society of Dermatology and Venerology (2013. 2. 7th)

G. 知的所有権の取得状況

1. 特許取得

<桑名正隆>

国際特許番号 : US Patent 8,216,838

(取得日：2012年7月10日)

出願人：学校法人慶應義塾

発明者：桑名正隆、加藤尚志、瀬田範行、宮崎洋

発明の名称：Method for efficient production of Monocyte-derived multipotent cell (MOMC)

2. 実用新案登録

なし

3. その他

なし

Ⅱ. 研究成果の刊行に関する一覧表

【雑誌】

| No. | 発表者氏名 | 論文タイトル | 発表誌名 | 巻号 | ページ | 出版年 |
|-----|---|--|-----------------------|--------|-----------|------|
| 1 | Yanaba K, Yoshizaki A, Asano Y, Kadono T, <u>Sato S</u> | Serum interleukin-9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis. | J Rheumatol | 38(10) | 2193-2197 | 2011 |
| 2 | Yoshizaki A, Yanaba K, Ogawa A, Iwata Y, Ogawa F, Takenaka M, Shimizu K, Asano Y, Kadono T, <u>Sato S</u> | The specific free radical scavenger edaravone suppresses fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. | Arthritis Rheum | 63(10) | 3086-3097 | 2011 |
| 3 | Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, <u>Sato S</u> | Immunization with DNA topoisomerase I and complete Freund's adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. | Arthritis Rheum | 63(11) | 3575-3585 | 2011 |
| 4 | Asano Y, Ihn H, Jinnin M, Tamaki K, <u>Sato S</u> | Altered dynamics of TGF- β receptors in scleroderma fibroblasts. | Arthritis Rheum | 70(2) | 384-387 | 2011 |
| 5 | Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, <u>Sato S</u> | Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. | Clin Rheumatol | 30(2) | 231-237 | 2011 |
| 6 | Hasegawa M, Fujimoto M, Hamaguchi Y, Matsushita T, Inoue K, <u>Sato S</u> , Takehara K | Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis. | J Rheumatol | 38(5) | 877-884 | 2011 |
| 7 | Kawashita Y, Jinnin M, Makino T, Kajihara I, Makino K, Honda N, Masuguchi S, Fukushima S, Inoue Y, <u>Ihn H</u> | Circulating miR-29a levels in patients with scleroderma spectrum disorder. | J Dermatol Sci | 61(1) | 67-69 | 2011 |
| 8 | Moriya C, Jinnin M, Yamane K, Maruo K, Muchemwa FC, Igata T, Makino T, Fukushima S, <u>Ihn H</u> | Expression of matrix metalloproteinase-13 is controlled by IL-13 via PI3K/Akt3 and PKC- δ in normal dermal fibroblasts. | J Invest Dermatol | 131(1) | 655-661 | 2011 |
| 9 | Tochimoto A, <u>Kawaguchi Y</u> , Hara M, Tateishi M, Fukasawa C, Takagi K, Nishimagi E, Ota Y, Katsumata Y, Gono T, Tanaka E, Yamanaka H | Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: four-year follow-up. | Mod Rheumatol | 21(3) | 296-301 | 2011 |
| 10 | Hoshino K, Satoh T, Kawaguchi Y, <u>Kuwana M</u> | Association of Hepatocyte Growth Factor promoter polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis. | Arthritis Rheum | 63(8) | 2465-2472 | 2011 |
| 11 | Furuya Y, <u>Kuwana M</u> | Effect of bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. | J Rheumatol | 38(10) | 2186-2192 | 2011 |
| 12 | Kajii, Suzuki C, Kashihara J, Kobayashi E, Kubo Y, Miyamoto H, Yuuki T, <u>Yamamoto T</u> , Nakae T | Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma. | Clin Exp Immunol | 163(2) | 235-241 | 2011 |
| 13 | Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Muroi E, <u>Ogawa F</u> , Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S | Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. | Ann Rheum Dis | 70(1) | 194-200 | 2011 |
| 14 | <u>Mugii N</u> , Hasegawa M, Matsushita T, Hamaguchi Y, Horie S, Yahata T, Inoue K, Someya F, Fujimoto M, Takehara K | Association between nail-fold capillary findings and disease activity in dermatomyositis. | Rheumatology | 50(6) | 1091-1098 | 2011 |
| 15 | Taniguchi T, Asano Y, Akamata K, Noda S, Masui Y, Yamada D, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T, <u>Sato S</u> | Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. | J Rheumatol | 39(3) | 539-544 | 2012 |
| 16 | Taniguchi T, Asano Y, Hatano M, Tamaki Z, Tomita M, Kawashima T, Miyazaki M, Sumida H, Akamata K, Takahashi T, Ichimura Y, Toyama T, Sugita M, Noda S, Yao A, Kinugawa K, <u>Sato S</u> | Effects of bosentan on non-digital ulcers in patients with systemic sclerosis. | Br J Dermatol | 166(2) | 417-421 | 2012 |
| 17 | Hasegawa M, <u>Asano Y</u> , Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Muro Y, Ogawa F, Sasaki T, Takahashi H, Tanaka S, Takehara K, Sato S. | Investigation of prognostic factors for skin sclerosis and lungfunction in Japanese patients with early systemic prospective observational study.sclerosis: a multicentre. | Rheumatology (Oxford) | 51(1) | 129-133 | 2012 |
| 18 | <u>Kuwana M</u> , Okazaki Y | Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols. | Ann Rheum Dis | 71(4) | 617-620 | 2012 |

| No. | 発表者氏名 | 論文タイトル | 発表誌名 | 巻号 | ページ | 出版年 |
|-----|---|--|--------------------|---------|-----------|------|
| 19 | Hasebe N, Kawasaki A, Ito I, Kawamoto M, Hasegawa M, Fujimoto M, Furukawa H, Tohma S, Sumida T, Takehara K, <u>Sato S</u> , Kawaguchi Y, Tsuchiya N | Association of UBE2L3 polymorphisms with diffuse cutaneous systemic sclerosis in a Japanese population. | Ann Rheum Dis | 71(7) | 1259-1260 | 2012 |
| 20 | Noda S, Asano Y, Akamata K, Aozasa N, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sumida H, Yanaba K, Tada Y, Sugaya M, Kadono T, <u>Sato S</u> | A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. | PLoS One | 7(2) | e32272 | 2012 |
| 21 | Yanaba K, Asano Y, Noda S, Akamata K, Aozasa N, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sumida H, Kuwano Y, Tada Y, Sugaya M, Kadono T, <u>Sato S</u> | Augmented production of soluble CD93 in patients with systemic sclerosis and clinical association with severity of skin sclerosis. | Br J Dermatol | 167(3) | 542-547 | 2012 |
| 22 | Noda S, Asano Y, Akamata K, Aozasa N, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sumida H, Yanaba Y, Tada Y, Sugaya M, Kadono T, <u>Sato S</u> | Constitutive activation of c-Abl/protein kinase C- δ /Fli pathway in dermal fibroblasts derived from patients with localized scleroderma. | Br J Dermatol | 167(5) | 1098-1105 | 2012 |
| 23 | Kajihara I, Jinnin M, Yamane K, Makino T, Honda N, Igata T, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, <u>Ihn H</u> | Increased accumulation of thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts. | Am J Pathol | 180(2) | 703-714 | 2012 |
| 24 | Honda N, Jinnin M, Kajiwara I, Makino T, Makino K, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, <u>Ihn H</u> | TGF- β -mediated down-regulation of microRNA-196a contributes to the constitutive up-regulated type I collagen expression in scleroderma dermal fibroblasts. | J Immunol | 188 | 3323-3331 | 2012 |
| 25 | Nakajima T, Jinnin M, Honda N, Kajihara I, Makino T, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, <u>Ihn H</u> | Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. | J Immunol | 188 | 3573-3583 | 2012 |
| 26 | Sing T, Jinnin M, Yamane K, Honda N, Makino K, Kajihara I, Makino T, Sakai K, Mashuguchi S, Fukushima S, <u>Ihn H</u> | microR-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. | Rheumatology | 51 | 1550-1556 | 2012 |
| 27 | Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, <u>Kuwana M</u> | Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-center cohort. | Rheumatology | 51(10) | 1846-1854 | 2012 |
| 28 | Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Huu DL, Iwakura Y, Fujimoto M, Takehara K | Potential roles of interleukin 17A in the development of skin fibrosis. | Arthritis Rheum | 64 (11) | 3726-3735 | 2012 |
| 29 | Wakatsuki-Nakamura T, Oyama N, <u>Yamamoto T</u> | Local injection of latency-associated peptide (LAP), a linker propeptide specific for active form of transforming growth factor-beta1 (TGF- β 1), inhibits dermal sclerosis in bleomycin-induced murine scleroderma. | Exp Dermatol | 21 | 189-194 | 2012 |
| 30 | Takahashi T, Asano Y, Akamata K, Aozasa N, Taniguchi T, Noda S, Masui Y, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T, <u>Sato S</u> | The dynamics of serum angiopoietin-2 levels correlates with the efficacy of intravenous cyclophosphamide pulse for interstitial lung disease associated with systemic sclerosis. | Mod Rheumatol | 23(5) | 884-890 | 2013 |
| 31 | Makino K, Jinnin M, Aoi J, Hirano A, Kajihara I, Makino T, Sakai K, Fukushima S, Inoue Y, <u>Ihn H</u> | Dicoidin domain receptor 2 -micro RNA 196a -mediated negative feedback against excess type I collagen expression is impaired in scleroderma dermal fibroblasts. | J Invest Dermatol | 133(1) | 110-119 | 2013 |
| 32 | Honda N, Jinnin M, Kira-Etoh T, Makino K, Kajihara I, Makino T, Fukushima S, Inoue Y, Okamoto Y, Hasegawa M, Fujimoto M, <u>Ihn H</u> | microRNA-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin β 3. | Am J Pathol | 182(1) | 206-216 | 2013 |
| 33 | Yamaguchi Y, <u>Kuwana M</u> | Proangiogenic hematopoietic cells of monocytic origin: roles in vascular regeneration and pathogenic processes of systemic sclerosis. | Histol Histopathol | 28(2) | 175-183 | 2013 |
| 34 | Arai M, Ikawa Y, Chujo S, Hamaguchi Y, Ishida W, Shirasaki F, Hasegawa M, Mukaida N, Fujimoto M, Takehara K | Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis. | J Dermatol Sci | 69(3) | 250-258 | 2013 |

| No. | 発表者氏名 | 論文タイトル | 発表誌名 | 巻号 | ページ | 出版年 |
|-----|--|--|-----------------------|--------------------|-----------|------|
| 35 | Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K | Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis. | Rheumatology | 52(2) | 242-251 | 2013 |
| 36 | Takehara K, Ihn H, Sato S | A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. | Clin Exp Rheumatol | 31 (2 Suppl 76) | 151-156 | 2013 |
| 37 | Noda S, Asano Y, Takahashi T, Akamata K, Aozasa N, Taniguchi T, Ichimura Y, Toyama T, Sumida H, Kuwana Y, Yanaba K, Tada Y, Sugaya M, Kadono T, Sato S | A possible contribution of decreased cathepsin V expression caused by Fli1 deficiency to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. | Rheumatology | 52(5) | 790-799 | 2013 |
| 38 | Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, Takehara K | Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. | Mod Rheumatol | 23(6) | 1076-1084 | 2013 |
| 39 | Asano Y, Trojanowska M | Fli1 represses transcription of the human $\alpha 2(I)$ collagen gene by recruitment of the HDAC1/p300 complex. | PLoS One | 8 | e74930 | 2013 |
| 40 | Masui Y, Asano Y, Shibata S, Noda S, Akamata K, Aozasa N, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sumida H, Yanaba K, Tada Y, Sugaya M, Sato S, Kadono T | A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response. | Rheumatology (Oxford) | 52 | 1239-1244 | 2013 |
| 41 | Ota Y, Kawaguchi Y, Takagi K, Ichida H, Gono T, Hanaoka M, Higuchi T, Yamanaka H | Ghrelin attenuates collagen production in lesional fibroblasts from patients with systemic sclerosis. | Clin Immunol | 147 | 71-78 | 2013 |
| 42 | Masuda A, Yasuoka H, Satoh T, Okazaki Y, Yamaguchi Y, Kuwana M | Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop. | Arthritis Res Ther | 15(4) | R74 | 2013 |
| 43 | Seta N, Okazaki Y, Miyazaki H, Kato T, Kuwana M | Platelet-derived stromal cell-derived factor-1 is required for the transformation of circulating monocytes into multipotential cells. | PLoS One | 8(9) | e74246 | 2013 |
| 44 | Amiya E, Takata M, Watanabe M, Takahashi T, Asano Y, Hatano M, Ozeki A, Watanabe A, Kawarasaki S, Tamaki Z, Taniguchi T, Ichimura Y, Toyama T, Nagai R, Sato S, Komuro I | Presence of desaturated hemoglobin enhances the contribution of blood cells to flow-mediated dilation in subjects with systemic sclerosis. | Int J Cardiol | 168(3) | 3125-3127 | 2013 |
| 45 | Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M | FTY720 ameliorates murine Scl-cGVHD by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. | Arthritis Rheum | 65(6) | 1624-1635 | 2013 |
| 46 | Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Tedder TF, Fujimoto M | Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. | Blood | 121 (16) | 3274-3283 | 2013 |
| 47 | Ueda-Hayakawa I, Hasegawa M, Hamaguchi Y, Takehara K, Fujimoto M | Circulating γ/δ T cells in systemic sclerosis exhibit activated phenotype and enhance gene expression of pro $\alpha 2(I)$ collagen of fibroblasts. | J Dermatol Sci | 69(1) | 54-60 | 2013 |

Ⅲ. 研究成果の刊行物・別刷

Serum Interleukin 9 Levels Are Increased in Patients with Systemic Sclerosis: Association with Lower Frequency and Severity of Pulmonary Fibrosis

KOICHI YANABA, AYUMI YOSHIZAKI, YOSHIHIDE ASANO, TAKAFUMI KADONO, and SHINICHI SATO

ABSTRACT. Objective. To determine serum interleukin 9 (IL-9) levels and their clinical associations in patients with systemic sclerosis (SSc).

Methods. Serum IL-9 levels were examined by ELISA in 71 patients with SSc, 15 with systemic lupus erythematosus (SLE), 15 with dermatomyositis (DM), 39 with atopic dermatitis, and 28 healthy individuals.

Results. Serum IL-9 levels were significantly elevated in SSc patients (84.6 ± 76.0 pg/ml) compared with healthy individuals (40.4 ± 41.7 pg/ml; $p < 0.001$), and patients with SLE (50.7 ± 52.0 pg/ml; $p < 0.05$) or DM (50.6 ± 55.8 pg/ml; $p < 0.05$) or atopic dermatitis (41.8 ± 38.8 pg/ml; $p < 0.001$). Among SSc patients, there were no differences in serum IL-9 levels between those with limited cutaneous SSc and those with diffuse cutaneous SSc. Patients with SSc and raised IL-9 levels less often had pulmonary fibrosis and decreased percentage vital capacity than those with normal IL-9 levels. IL-9 levels were positively correlated with percentage vital capacity in patients with SSc.

Conclusion. Serum IL-9 level was increased in patients with SSc, and was associated with lower frequency and severity of pulmonary fibrosis in SSc. IL-9 could be a protective factor against the development of pulmonary fibrosis in this disease, and as such would be a possible therapeutic target. (First Release Aug 1 2011; J Rheumatol 2011;38:2193-7; doi:10.3899/jrheum.110268)

Key Indexing Terms:

CYTOKINE

ELISA

INTERLEUKIN 9

PULMONARY FIBROSIS

SYSTEMIC SCLEROSIS

Systemic sclerosis (SSc) is a generalized connective tissue disorder characterized by sclerotic and vascular changes in the skin and various internal organs. It is generally regarded as an autoimmune disorder because of the presence of antinuclear antibodies. Although the pathogenesis of SSc remains unclear, many studies have suggested that cytokines or growth factors regulate its induction by stimulating the synthesis of extracellular matrix components, which may injure endothelial cells and modulate the function of leukocytes^{1,2}. These cytokines or growth factors are produced in part by inflammatory cells infiltrating the affected tissues, such as skin or lungs, of patients with SSc^{1,2,3}.

An imbalance between Th (T helper) 1 and Th2 immune responses is considered to play an important role in

auto-immune diseases. Although the Th1/Th2 imbalance in SSc appears to be complicated, SSc is mainly thought of as a Th2-dominant autoimmune disease. Serum levels of interleukin 4 (IL-4) and IL-13, both representative Th2 cytokines, are significantly elevated in patients with SSc compared with healthy individuals^{4,5,6}, with IL-4 levels gradually decreasing as skin sclerosis improves⁷. By contrast, serum levels of IL-12, a Th1-inducing cytokine, are lower in the early phase of SSc than in healthy individuals, but increase in later phases⁷. Lymphocytes from patients with clinically active SSc produce lower amounts of interferon- γ , a representative Th1 cytokine, than those from patients with clinically stable disease⁸. Further, it has recently been reported that serum IL-17 levels are significantly increased in patients with SSc⁹, while IL-17 is also overproduced by T cells in the skin and lungs of SSc patients¹⁰.

IL-9 is a T cell-derived pleiotropic cytokine that was initially identified as a Th2 cytokine¹¹. A number of CD4-positive T cell subsets, named Th9, have recently been shown to share the capacity to secrete IL-9^{12,13}. IL-9 targets cells of the lymphoid, myeloid, and mast cell lineages, as well as lung epithelial cells, and is likely to contribute to the development of allergic and autoimmune diseases such as asthma, silica-induced lung fibrosis, and experimental autoimmune encephalomyelitis^{14,15,16,17}. However, it is unclear whether IL-9 exerts mainly proinflammatory or antiinflammatory activities. We suggest that it plays a role in the pathogenesis

From the Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo; and Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Supported by a grant for Research on Intractable Diseases from the Ministry of Health, Labor and Welfare of Japan.

K. Yanaba, MD, PhD, Department of Dermatology, Faculty of Medicine, University of Tokyo; A. Yoshizaki, MD, Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences; Y. Asano, MD, PhD; T. Kadono, MD, PhD; S. Sato, MD, PhD, Department of Dermatology, Faculty of Medicine, University of Tokyo.

Address correspondence to Dr. K. Yanaba, Department of Dermatology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail: yanabak-der@h.u-tokyo.ac.jp

Accepted for publication May 9, 2011.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2011. All rights reserved.

of SSc; in this study, we examined serum IL-9 levels in patients with SSc, and evaluated the results with respect to clinical features.

MATERIALS AND METHODS

Patients. Serum samples were obtained from 71 Japanese patients with SSc (58 women, 13 men) with a mean age of 51 years (range 14–77 yrs). All patients fulfilled criteria for SSc proposed by the American College of Rheumatology (ACR)¹⁸. Patients were classified¹⁹ into limited cutaneous SSc (lcSSc; n = 29) and diffuse cutaneous SSc (dcSSc; n = 42) groups. The mean disease duration was 4.8 ± 6.8 years (range 0.2–32 yrs). Duration was calculated from the time of onset of the first clinical event (other than Raynaud's phenomenon) that was a clear manifestation of SSc.

Fifteen patients with systemic lupus erythematosus (SLE) who fulfilled the ACR criteria²⁰, 15 with dermatomyositis (DM) who fulfilled the criteria of Bohan and Peter²¹, and 39 patients with atopic dermatitis (AD) who fulfilled the proposed AD criteria²² acted as disease controls. Twenty-eight age- and sex-matched healthy Japanese individuals served as healthy controls.

Antinuclear antibodies were identified by indirect immunofluorescence using HEp-2 cells as the substrate, and autoantibody specificities were further assessed by ELISA and immunoprecipitation.

At the first visit, 5 patients had been treated with low-dose steroids (prednisolone 5–20 mg/day) and 4 with low-dose D-penicillamine (100–500 mg/day). None of the patients had received immunosuppressive treatment.

Clinical assessment. Complete medical histories, physical examinations, and laboratory tests were conducted for all patients at their first visit. Organ system involvement was defined as described^{23,24}. Lung involvement (bibasilar fibrosis) was observed using high-resolution computed tomography (HRCT); esophagus hypomotility was determined by barium radiography; heart involvement was indicated as pericarditis, congestive heart failure, or arrhythmias requiring treatment; kidney involvement was indicated by malignant hypertension and rapidly progressive renal failure with no other explanation; and proximal muscle weakness and elevated serum creatine kinase indicated muscle involvement. Pulmonary fibrosis was defined as bibasilar interstitial fibrosis on chest HRCT. In addition, a pulmonary function test (PFT), including vital capacity (VC) and DLCO, was evaluated to examine the severity of pulmonary fibrosis. When DLCO and VC were < 75% and < 80%, respectively, of the predicted normal values, they were considered abnormal. Patients with SSc who were smokers or had other respiratory disorders that could have affected %DLCO or %VC were excluded from our study. Sixty-nine of 71 patients with SSc had pulmonary function test data available. Pulmonary artery pressure was estimated by Doppler echocardiogram. The modified Rodnan total skin thickness score (TSS) was measured by summing skin thickness measurements, and determined by palpation on a 0–3 scale in 17 body areas²⁵.

The study protocol was approved by the Nagasaki University Graduate School of Biomedical Sciences and Nagasaki University Hospital, and informed consent was obtained from all patients.

ELISA. Fresh venous blood samples were drawn into pyrogen-free blood collection tubes without additives, immediately immersed in melting ice, and allowed to clot 1 h before centrifugation. Only sera were separated. All serum samples were stored at –70°C before use. All these procedures were standardized. Serum IL-9 levels were measured with specific ELISA kits (BioLegend, San Diego, CA, USA), according to the manufacturer's protocol. Each sample was tested in duplicate. The detection limit of this assay was 0.5 pg/ml. Serum levels of Krebs von den Lungen (KL)-6 and surfactant protein-D (SP-D), both serological markers of pulmonary fibrosis, were investigated using specific ELISA kits (Eitest KL-6, Eisai, Tokyo, Japan, and SP-D kit, Yamasa, Chiba, Japan, respectively), according to the manufacturer's protocol.

Statistical analysis. The Mann-Whitney U test was used to compare IL-9 levels, the Fisher's exact probability test to compare frequencies, and Bonferroni's test for multiple comparisons. Spearman's rank correlation coefficient was used to examine the relationship between 2 continuous variables.

Nonlinear regression was used to examine the relationship between independent variables and their associated observed dependent variables. A probability value of $p < 0.05$ was considered significant.

RESULTS

Antinuclear antibodies. Antitopoisomerase I antibodies were positive in 25 patients, anticentromere antibodies in 26, anti-RNA polymerase I and III antibodies in 6, anti-U1RNP antibodies in 4, anti-U3RNP antibodies in one, anti-Th/To antibodies in one, and 8 patients had negative results for these antibodies.

Serum IL-9 levels are elevated in patients with SSc. Serum IL-9 levels at the first visit were significantly higher in SSc patients (84.6 ± 76.0 pg/ml) than in healthy individuals (40.4 ± 41.7 pg/ml; $p < 0.001$; Figure 1), SLE patients (50.7 ± 52.0 pg/ml; $p < 0.05$), DM patients (50.6 ± 55.8 pg/ml; $p < 0.05$), and AD patients (41.8 ± 38.8 pg/ml; $p < 0.001$). Concerning SSc subgroups, IL-9 levels in patients with dcSSc (76.9 ± 67.5 pg/ml) and lcSSc (95.8 ± 86.8 pg/ml) were increased compared with healthy individuals ($p < 0.01$ and $p < 0.01$, respectively). There was no significant difference in serum IL-9 levels between dcSSc patients and lcSSc patients.

Increased IL-9 levels are associated with a lower frequency and severity of pulmonary fibrosis. Clinical and laboratory variables obtained at the first evaluation were compared between SSc patients with elevated IL-9 levels and those with normal IL-9 levels. Values higher than the mean + 2 SD (123.9 pg/ml) of control serum samples were considered to be elevated in this study. Elevated IL-9 levels were observed in 21% (15/71) of all SSc patients, 17% (7/42) of dcSSc patients, and 28% (8/29) of lcSSc patients. As shown in Table 1, the frequency of pulmonary fibrosis and decreased %VC in SSc patients with elevated IL-9 levels was significantly lower than in those with normal IL-9 levels (27% vs 57%; $p < 0.05$; and 0% vs 33%; $p < 0.01$, respectively). Serum IL-9 levels did not correlate with disease duration and the presence of antitopoisomerase I antibody and anticentromere antibody. Further, there was no significant difference in serum IL-9 levels between patients with disease duration < 2 years and those with disease duration > 2 years (data not shown).

Serum IL-9 levels were positively correlated with %VC in patients with SSc ($r^2 = 0.32$, $p < 0.01$; Figure 2). Further, we investigated correlations of serum IL-9 levels with serum KL-6, which is a mucin-like high molecular weight glycoprotein²⁶ and a marker of pulmonary fibrosis in patients with SSc²⁷, and SP-D, which is produced and secreted by alveolar type II pneumocytes in alveoli and Clara cells and is also a marker of pulmonary fibrosis in patients with SSc²⁸. Serum IL-9 levels correlated inversely with serum KL-6 levels ($r = 0.51$, $p < 0.01$) and SP-D levels ($r = -0.42$, $p < 0.05$) determined by ELISA. Consistent with these findings, IL-9 levels were significantly lower in SSc patients with pulmonary fibrosis observed using HRCT and decreased %VC (Figure 3). Further, SSc patients who had both pulmonary fibrosis




Figure 1. Serum interleukin (IL)-9 levels in patients with systemic sclerosis (SSc), diffuse cutaneous SSc (dcSSc), limited cutaneous SSc (lcSSc), systemic lupus erythematosus (SLE), dermatomyositis (DM), atopic dermatitis (AD), and healthy individuals (Control). Serum IL-9 levels were determined by a specific ELISA. Bars indicate mean values in each group. Broken line indicates the cutoff value (mean + 2 SD of control values).

using HRCT and abnormal PFT (decreased %VC and/or decreased %DLCO) had significantly lower IL-9 levels. Thus, raised IL-9 levels were associated with a lower frequency and severity of pulmonary fibrosis.

DISCUSSION

This is the first report of elevated serum IL-9 levels in patients with SSc (Figure 1). IL-9 levels were raised not only in patients with dcSSc, but also in those with lcSSc, and were associated with a lower prevalence of pulmonary involvement and better pulmonary function (Table 1, Figures 2 and 3). Thus, elevated IL-9 levels may be protective against the development of pulmonary fibrosis in SSc.

IL-4 production is enhanced by silica administration, which also induces Th2 polarization¹⁷. As serum IL-4 levels are raised in SSc patients^{4,5,6} and contribute to the differentiation of naive CD4-positive T cells into Th9 cells together with transforming growth factor- β (TGF- β)^{12,13}, a Th2-polarized condition is likely to drive IL-9 production. Moreover, IL-9 overexpression reduces the severity of silica-induced lung fibrosis in mice¹⁷. Our data suggest that IL-9 may play a protective role in the development of pulmonary fibrosis. It has also been demonstrated that IL-9 in combination with TGF- β increases the production of Th17 cells¹⁶. Although serum IL-17 levels are increased in patients with SSc, elevated IL-17 levels tend to correlate with a lower frequency and

severity of lung fibrosis, suggesting that IL-17 production in SSc serves as a protective factor⁹. Interestingly, IL-9 also enhances the suppressive function of regulatory T cells¹⁶. Thus increased IL-9 may induce IL-17 production and regulatory T cell activation, thereby inhibiting the development of pulmonary fibrosis in SSc.

It has been shown that overexpression of IL-9 enhances the recruitment of B cells in the lung in murine silica-induced pulmonary fibrosis¹⁷. Further, B cell deficiency abolishes the protective effect of IL-9²⁹. Therefore, IL-9 is likely to have a protective role in the development of lung fibrosis through the recruitment of B cells. Moreover, the numbers of B cells are elevated in the lungs of SSc patients with interstitial lung disease³⁰ and recent studies show that B cells and specific B cell subsets can negatively regulate immune responses, validating the existence of regulatory B cells^{31,32}. These findings suggest that IL-9 may play a key role in the regulation of lung involvement in SSc by enhancing regulatory B cell recruitment in the lungs. Further studies examining the contribution of IL-9 to the regulation of interstitial lung disease and other organ involvement in SSc are required. Moreover, it is essential to examine the longitudinal changes of serum IL-9 levels in patients with SSc and to assess the association with disease activity. Nonetheless, the results of our study suggest that the administration of IL-9 might be a possible treatment in patients with SSc who have severe interstitial lung disease.

Table 1. Clinical and laboratory findings among systemic sclerosis (SSc) patients with elevated serum IL-9 levels. Unless noted otherwise, values are percentages.

| | Elevated IL-9, n = 15 | Normal IL-9, n = 56 |
|----------------------------------|--------------------------|------------------------|
| Age at onset, yrs, mean ± SD | 44 ± 9 | 47 ± 14 |
| Male:female | 3:12 | 10:46 |
| Disease duration, yrs, mean ± SD | 4.5 ± 7.1 | 4.8 ± 6.8 |
| TSS, points, mean ± SD | 10.9 ± 7.7 | 14.2 ± 9.6 |
| Clinical features | | |
| dcSSc | 47 | 63 |
| lcSSc | 53 | 37 |
| Pitting scars/ulcers | 33 | 41 |
| Contracture of phalanges | 45 | 33 |
| Diffuse pigmentation | 53 | 50 |
| Telangiectasia | 47 | 39 |
| Organ involvement | | |
| Pulmonary fibrosis | 27* | 57 |
| Decreased % VC | 0** | 33 |
| Decreased % DLCO | 40 | 63 |
| Pulmonary hypertension | 20 | 13 |
| Esophagus | 60 | 48 |
| Heart | 0 | 5 |
| Kidney | 0 | 2 |
| Joint | 13 | 14 |
| Muscle | 7 | 5 |
| Laboratory findings | | |
| Antitopoisomerase I antibody | 33 | 38 |
| Anticentromere antibody | 47 | 36 |
| Increased IgG | 40 | 29 |
| Elevated ESR | 47 | 42 |
| Elevated CRP | 13 | 13 |

* p < 0.05, ** p < 0.01 vs SSc patients with normal serum IL-9 levels. ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TSS: Rodnan total skin thickness score; dcSSc: diffuse cutaneous SSc; lcSSc: limited cutaneous SSc; VC: vital capacity; IL: interleukin.

REFERENCES

- White B. Immunopathogenesis of systemic sclerosis. *Rheum Dis Clin North Am* 1996;32:695-708.
- Furst DE, Clements PJ. Hypothesis for the pathogenesis of systemic sclerosis. *J Rheumatol Suppl.* 1997 May;48:53-7.
- Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. *Curr Opin Rheumatol* 1999;11:503-7.
- Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor- α , and interferon- γ levels in sera from patients with scleroderma. *Arthritis Rheum* 1992;35:67-72.
- Famularo G, Procopio A, Giacomelli R, Danese C, Sacchetti S, Perego MA, et al. Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. *Clin Exp Immunol* 1990;81:368-72.
- Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. *J Rheumatol* 1997;24:328-32.
- Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. *J Rheumatol* 2006;33:275-84.
- Molteni M, Della Bella S, Mascagni B, Bazzi S, Zulian C, Compasso S, et al. Increased interferon- γ (IFN- γ) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and




Figure 2. Correlation of serum interleukin (IL)-9 levels with percent vital capacity (VC), serum Krebs von den Lungen (KL)-6 levels, and surfactant protein-D (SP-D) levels in patients with systemic sclerosis. Serum IL-9, KL-6, and SP-D levels were determined by a specific ELISA. Broken line indicates the cutoff value of IL-9.

- Raynaud's phenomenon. *Clin Exp Immunol* 1999;116:164-8.
- Murata M, Fujimoto M, Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? *J Dermatol Sci* 2008;50:240-2.
- Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al. Increased interleukin-17 production in patients with systemic sclerosis. *Arthritis Rheum* 2000;43:2455-63.
- Knoops L, Renaud JC. IL-9 and its receptor: from signal




Figure 3. Serum interleukin (IL)-9 levels at first visit in the presence and absence of pulmonary fibrosis observed using high-resolution computed tomography (HRCT), decrease in percent vital capacity (VC), and both pulmonary fibrosis using HRCT and abnormal pulmonary function test (PFT; decreased %VC and/or DLCO). Bars indicate mean values in each group. Broken line indicates the cutoff value.

- transduction to tumorigenesis. *Growth Factors* 2004;22:207-15.
12. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, et al. Transforming growth factor- β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. *Nat Immunol* 2008;9:1341-6.
 13. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, et al. IL-4 inhibits TGF- β -induced Foxp3+ T cells and, together with TGF- β , generates IL-9+ IL-10+ Foxp3- effector T cells. *Nat Immunol* 2008;9:1347-55.
 14. Soroosh P, Doherty TA. Th9 and allergic disease. *Immunology* 2009;127:450-8.
 15. Nowak EC, Noelle RJ. Interleukin-9 as a T helper type 17 cytokine. *Immunology* 2010;131:169-73.
 16. Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola E, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. *Proc Natl Acad Sci USA* 2009;106:12885-90.
 17. Arras M, Huaux F, Vink A, Delos M, Coutelier JP, Many MC, et al. Interleukin-9 reduces lung fibrosis and type 2 immune polarization induced by silica particles in a murine model. *Am J Respir Cell Mol Biol* 2001;24:368-75.
 18. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). *Arthritis Rheum* 1980;23:581-90.
 19. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. *J Rheumatol* 1988;15:202-5.
 20. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271-7.
 21. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). *N Engl J Med* 1975;292:344-8.
 22. Rajka G, Langeland T. Grading of severity of atopic dermatitis. *Acta Derm Venerol* 1989;144:13-4.
 23. Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. *Arthritis Rheum* 1988;31:196-203.
 24. Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. *Arthritis Rheum* 1994;37:391-4.
 25. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. *J Rheumatol* 1993;20:1892-6.
 26. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. *Jpn J Clin Oncol* 1988;18:203-16.
 27. Yanaba K, Hasegawa M, Hamaguchi Y, Fujimoto M, Takehara K, Sato S. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. *Clin Exp Rheumatol* 2003;21:429-36.
 28. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. *J Rheumatol* 2004;31:1112-20.
 29. Arras M, Louahed J, Simoen V, Barbarin V, Misson P, van den Brule S, et al. B lymphocytes are critical for lung fibrosis control and prostaglandin E2 regulation in IL-9 transgenic mice. *Am J Respir Cell Mol Biol* 2006;34:573-80.
 30. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. *Arthritis Rheum* 2007;56:3167-8.
 31. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. *Immunity* 2008;28:639-50.
 32. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. *Immunol Rev* 2008;224:201-14.

The Specific Free Radical Scavenger Edaravone Suppresses Fibrosis in the Bleomycin-Induced and Tight Skin Mouse Models of Systemic Sclerosis

Ayumi Yoshizaki,¹ Koichi Yanaba,¹ Asako Ogawa,¹ Yohei Iwata,¹ Fumihide Ogawa,¹ Motoi Takenaka,¹ Kazuhiro Shimizu,¹ Yoshihide Asano,² Takafumi Kadono,² and Shinichi Sato²

Objective. Patients with systemic sclerosis (SSc) exhibit enhanced production of free radicals due to ischemia and reperfusion injury following Raynaud's phenomenon, an initial clinical manifestation. Oxidative stress induces cytokine production, inflammatory cell recruitment, and tissue injury in several inflammatory diseases. The aim of this study was to examine the effect of edaravone, a free radical scavenger, on the development of fibrosis and autoimmunity in two different mouse models of SSc.

Methods. The bleomycin-induced SSc model in mice and the tight skin mouse model were used to evaluate the effect of edaravone on fibrosis and immunologic abnormalities. To assess the reaction of fibroblasts to stimulation with free radicals, fibroblasts from these mice were cultured with NONOate, a nitric oxide-releasing agent, and hydrogen peroxide.

Results. Treatment with edaravone reduced fibrosis in mice with bleomycin-induced SSc and in TSK/+ mice. The production of free radicals was also attenuated by edaravone in both models. In addition, production of fibrogenic cytokines such as interleukin-6 and

transforming growth factor β 1, production of anti-topoisomerase I antibody, and the degree of hypergammaglobulinemia were reduced by edaravone. Furthermore, bleomycin induced the production of H_2O_2 and nitric oxide from inflammatory cells, and collagen production was increased in fibroblasts cultured with H_2O_2 and NONOate.

Conclusion. This study is the first to show that edaravone has a significant inhibitory effect on fibrosis both in the bleomycin-induced SSc model and in TSK/+ mice. These results indicate that edaravone should be further evaluated for potential use as an antifibrotic agent in SSc.

Systemic sclerosis (SSc) is a connective tissue disease characterized by vascular damage, excessive accumulation of extracellular matrix (ECM), and fibrosis in the skin and other visceral organs, on an autoimmune background (1,2). Although the pathogenesis of SSc remains unknown, it has been proposed that oxidative stress, microvasculature, and the immune system play an important role in disease development (3,4). Many previous studies have confirmed that production of free radicals, such as hydroxyl radicals and peroxynitrite radicals, is enhanced in human SSc patients, due to ischemia and reperfusion injury following Raynaud's phenomenon, an initial clinical manifestation (5,6). Raynaud's phenomenon is accompanied by the presence of proinflammatory cytokines and the loss of redox control, leading to oxidative stress (7). In addition, mice treated with agents that induce the release of free radicals, such as hydroxyl radicals and peroxynitrite radicals, exhibit cutaneous and lung fibrosis (8). Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with SSc and are correlated with

Supported by the Ministry of Health, Labor, and Welfare of Japan (Research on Intractable Diseases grant to Drs. Yoshizaki and Sato).

¹Ayumi Yoshizaki, MD, PhD, Koichi Yanaba, MD, PhD, Asako Ogawa, MD, Yohei Iwata, MD, PhD, Fumihide Ogawa, MD, PhD, Motoi Takenaka, MD, PhD, Kazuhiro Shimizu, MD, PhD: Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; ²Yoshihide Asano, MD, PhD, Takafumi Kadono, MD, PhD, Shinichi Sato, MD, PhD: University of Tokyo Graduate School of Medicine, Tokyo, Japan.

Address correspondence to Shinichi Sato, MD, PhD, Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail: satos-der@h.u-tokyo.ac.jp.

Submitted for publication July 17, 2010; accepted in revised form May 19, 2011.